信达生物-话题@MedSci

#信达生物#

29篇内容 | 1981人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2176666, encodeId=f92721e66660c, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a> <a href='/topic/show?id=4a691563543' target=_blank style='color:#2F92EE;'>#ROS1阳性肺癌#</a> <a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a> <a href='/topic/show?id=02c810903654' target=_blank style='color:#2F92EE;'>#泰莱替尼#</a> <a href='/topic/show?id=495f10903e6e' target=_blank style='color:#2F92EE;'>#葆元医药#</a>, objectTitle=新一代强效ROS1抑制剂泰莱替尼（AB-106）获优先审评资格！cORR高达92.5%, objectType=article, longId=806499, objectId=754b80649999, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231222/1703299579204_4754896.jpg, objectUrl=/article/show_article.do?id=754b80649999, replyNumber=0, likeNumber=102, createdTime=2023-12-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=754b80649999, moduleTitle=新一代强效ROS1抑制剂泰莱替尼（AB-106）获优先审评资格！cORR高达92.5%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=754b80649999)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1465483, encodeId=c1f2146548391, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=驯鹿生物与信达生物共同开发的全人源BCMA CAR-T细胞伊基仑赛注射液新药申请上市, objectType=article, longId=728560, objectId=ec8be2856007, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec8be2856007, replyNumber=0, likeNumber=80, createdTime=2022-06-04, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec8be2856007, moduleTitle=驯鹿生物与信达生物共同开发的全人源BCMA CAR-T细胞伊基仑赛注射液新药申请上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec8be2856007)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465482, encodeId=ef7c146548263, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=FDA-ODAC后，信达生物PD-1官方回应来了！, objectType=article, longId=295480, objectId=7ac32954800c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ac32954800c, replyNumber=0, likeNumber=69, createdTime=2022-02-13, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ac32954800c, moduleTitle=FDA-ODAC后，信达生物PD-1官方回应来了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ac32954800c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465481, encodeId=4e3514654819a, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物(01801)与UNION达成战略合作引进用于治疗炎症性皮肤病的下一代PDE4抑制剂, objectType=article, longId=217823, objectId=dc8421e823de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc8421e823de, replyNumber=0, likeNumber=89, createdTime=2021-09-30, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc8421e823de, moduleTitle=信达生物(01801)与UNION达成战略合作引进用于治疗炎症性皮肤病的下一代PDE4抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc8421e823de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465480, encodeId=1d4f146548003, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物与劲方医药关于GFH925（KRAS G12C抑制剂）达成全球战略合作, objectType=article, longId=216609, objectId=cb44216609d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb44216609d0, replyNumber=0, likeNumber=84, createdTime=2021-09-04, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb44216609d0, moduleTitle=信达生物与劲方医药关于GFH925（KRAS G12C抑制剂）达成全球战略合作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb44216609d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465479, encodeId=5d3514654e9bc, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物PI3Kδ抑制剂parsaclisib拟纳入突破性治疗品种, objectType=article, longId=208978, objectId=80682089e8c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80682089e8c1, replyNumber=0, likeNumber=95, createdTime=2021-03-26, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80682089e8c1, moduleTitle=信达生物PI3Kδ抑制剂parsaclisib拟纳入突破性治疗品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80682089e8c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465478, encodeId=40c414654e891, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, objectType=article, longId=207677, objectId=f31920e677cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31920e677cb, replyNumber=0, likeNumber=71, createdTime=2021-02-28, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31920e677cb, moduleTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31920e677cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465477, encodeId=a22c14654e7f6, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, objectType=article, longId=203674, objectId=94d42036e4b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d42036e4b2, replyNumber=0, likeNumber=55, createdTime=2020-11-25, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d42036e4b2, moduleTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94d42036e4b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465476, encodeId=afcb14654e67b, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤, objectType=article, longId=201941, objectId=0be8201941c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be8201941c7, replyNumber=0, likeNumber=74, createdTime=2020-10-12, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be8201941c7, moduleTitle=信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be8201941c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465475, encodeId=c0eb14654e5b3, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物贝伐珠单抗生物类似药——达攸同上市, objectType=article, longId=196189, objectId=c48d19618953, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c48d19618953, replyNumber=0, likeNumber=84, createdTime=2020-06-22, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c48d19618953, moduleTitle=信达生物贝伐珠单抗生物类似药——达攸同上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c48d19618953)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465474, encodeId=079314654e4e9, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议, objectType=article, longId=195728, objectId=ce9d195e287e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce9d195e287e, replyNumber=0, likeNumber=101, createdTime=2020-06-13, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce9d195e287e, moduleTitle=CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce9d195e287e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465473, encodeId=8d5a14654e311, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), objectType=article, longId=194241, objectId=a91619424150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91619424150, replyNumber=0, likeNumber=77, createdTime=2020-05-17, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91619424150, moduleTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91619424150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465472, encodeId=66a414654e2cf, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物与Alector合作在中国开发抗肿瘤的SIRP-α单抗, objectType=article, longId=190928, objectId=d3031909289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3031909289d, replyNumber=0, likeNumber=81, createdTime=2020-03-28, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3031909289d, moduleTitle=信达生物与Alector合作在中国开发抗肿瘤的SIRP-α单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3031909289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465471, encodeId=69eb14654e1f6, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=中外合作PD-1药物受关注，信达生物将与礼来开启后续合作, objectType=article, longId=183422, objectId=e52518342241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e52518342241, replyNumber=0, likeNumber=86, createdTime=2019-11-24, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e52518342241, moduleTitle=中外合作PD-1药物受关注，信达生物将与礼来开启后续合作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e52518342241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465470, encodeId=0c1d14654e045, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, objectType=article, longId=178540, objectId=b7281e8540c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7281e8540c0, replyNumber=0, likeNumber=62, createdTime=2019-09-03, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7281e8540c0, moduleTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7281e8540c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465469, encodeId=acd5146546997, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA, objectType=article, longId=168735, objectId=7d54168e353a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d54168e353a, replyNumber=0, likeNumber=73, createdTime=2019-06-20, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d54168e353a, moduleTitle=信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d54168e353a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465468, encodeId=ab3d1465468fb, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=2019 ASCO：信达生物发布其贝伐单抗生物仿制药IBI305的安全性数据, objectType=article, longId=167617, objectId=95d816e61754, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95d816e61754, replyNumber=0, likeNumber=73, createdTime=2019-06-05, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95d816e61754, moduleTitle=2019 ASCO：信达生物发布其贝伐单抗生物仿制药IBI305的安全性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95d816e61754)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465467, encodeId=38f5146546e62, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物宣布2018年年度业绩, objectType=article, longId=162367, objectId=e85f16236ec5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e85f16236ec5, replyNumber=0, likeNumber=73, createdTime=2019-03-16, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e85f16236ec5, moduleTitle=信达生物宣布2018年年度业绩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e85f16236ec5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465466, encodeId=8ad6146546657, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物获2018“亚太区年度IPO”暨年度“更佳香港股票发行奖”, objectType=article, longId=161350, objectId=2713161350cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2713161350cb, replyNumber=0, likeNumber=86, createdTime=2019-03-01, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2713161350cb, moduleTitle=信达生物获2018“亚太区年度IPO”暨年度“更佳香港股票发行奖”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2713161350cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1465465, encodeId=540e1465465c1, content=<a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a>, objectTitle=信达生物即将在国内推出PD-1单抗, objectType=article, longId=160826, objectId=ab1d1608262e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab1d1608262e, replyNumber=0, likeNumber=110, createdTime=2019-02-24, rootId=0, userName=yytms, userId=26526732817, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab1d1608262e, moduleTitle=信达生物即将在国内推出PD-1单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab1d1608262e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

信达生物

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#ROS1# #ROS1阳性肺癌# #信达生物# #泰莱替尼# #葆元医药#

新一代强效ROS1抑制剂泰莱替尼（AB-106）获优先审评资格！cORR高达92.5%

2023-12-23发表于威斯康星

yytms (审核中...)

前往app查看评论内容

#信达生物#

驯鹿生物与信达生物共同开发的全人源BCMA CAR-T细胞伊基仑赛注射液新药申请上市

2022-06-04

yytms (审核中...)

前往app查看评论内容

#信达生物#

FDA-ODAC后，信达生物PD-1官方回应来了！

2022-02-13

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物(01801)与UNION达成战略合作引进用于治疗炎症性皮肤病的下一代PDE4抑制剂

2021-09-30

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物与劲方医药关于GFH925（KRAS G12C抑制剂）达成全球战略合作

2021-09-04

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物PI3Kδ抑制剂parsaclisib拟纳入突破性治疗品种

2021-03-26

yytms (审核中...)

前往app查看评论内容

#信达生物#

礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市

2021-02-28

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果

2020-11-25

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤

2020-10-12

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物贝伐珠单抗生物类似药——达攸同上市

2020-06-22

yytms (审核中...)

前往app查看评论内容

#信达生物#

CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议

2020-06-13

yytms (审核中...)

前往app查看评论内容

#信达生物#

ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究)

2020-05-17

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物与Alector合作在中国开发抗肿瘤的SIRP-α单抗

2020-03-28

yytms (审核中...)

前往app查看评论内容

#信达生物#

中外合作PD-1药物受关注，信达生物将与礼来开启后续合作

2019-11-24

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当

2019-09-03

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA

2019-06-20

yytms (审核中...)

前往app查看评论内容

#信达生物#

2019 ASCO：信达生物发布其贝伐单抗生物仿制药IBI305的安全性数据

2019-06-05

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物宣布2018年年度业绩

2019-03-16

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物获2018“亚太区年度IPO”暨年度“更佳香港股票发行奖”

2019-03-01

yytms (审核中...)

前往app查看评论内容

#信达生物#

信达生物即将在国内推出PD-1单抗

2019-02-24

科室
- - 订阅+
  - 更多科室
工具
服务